ZA906670B - Compounds for the reversal of multidrug resistance of cancer cells against cytotoxic drugs - Google Patents

Compounds for the reversal of multidrug resistance of cancer cells against cytotoxic drugs

Info

Publication number
ZA906670B
ZA906670B ZA906670A ZA906670A ZA906670B ZA 906670 B ZA906670 B ZA 906670B ZA 906670 A ZA906670 A ZA 906670A ZA 906670 A ZA906670 A ZA 906670A ZA 906670 B ZA906670 B ZA 906670B
Authority
ZA
South Africa
Prior art keywords
reversal
compounds
cancer cells
multidrug resistance
cells against
Prior art date
Application number
ZA906670A
Other languages
English (en)
Inventor
Adrian Llewellyn Harris
Llewellyn Harris Adrian
Lauri Veikko Matti Kangas
Veikko Matti Kangas Lauri
Michael William Degregorio
William Degregorio Michael
Original Assignee
Llewellyn Harris Adrian
Veikko Matti Kangas Lauri
William Degregorio Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Llewellyn Harris Adrian, Veikko Matti Kangas Lauri, William Degregorio Michael filed Critical Llewellyn Harris Adrian
Publication of ZA906670B publication Critical patent/ZA906670B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA906670A 1989-08-23 1990-08-22 Compounds for the reversal of multidrug resistance of cancer cells against cytotoxic drugs ZA906670B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/397,551 US4990538A (en) 1989-08-23 1989-08-23 Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs

Publications (1)

Publication Number Publication Date
ZA906670B true ZA906670B (en) 1991-06-26

Family

ID=23571649

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA906670A ZA906670B (en) 1989-08-23 1990-08-22 Compounds for the reversal of multidrug resistance of cancer cells against cytotoxic drugs

Country Status (11)

Country Link
US (1) US4990538A (de)
EP (1) EP0415623A3 (de)
JP (1) JP3186759B2 (de)
KR (1) KR0171893B1 (de)
AU (1) AU633954B2 (de)
CA (1) CA2023630C (de)
HU (1) HU215913B (de)
IE (1) IE67639B1 (de)
NZ (1) NZ234999A (de)
PH (1) PH27064A (de)
ZA (1) ZA906670B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5114951A (en) * 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5162581A (en) * 1989-05-29 1992-11-10 Takaru Shuzo Co., Ltd. Crystalline deoxyspergualin, process for its preparation and suppository containing the same
GB8914062D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914060D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914040D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5114919A (en) * 1990-02-26 1992-05-19 Merck & Co., Inc. Adjuncts in cancer chemotherapy
ITRM910192A1 (it) * 1990-04-03 1991-10-04 American Cyanamid Co Metodo per invertire la resistenza a bisantrene mediata da p-glicoproteine.
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ES2094525T3 (es) * 1992-02-06 1997-01-16 Merrell Pharma Inc Anulacion de resistencia a multiples farmacos por tetraariletilenos.
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5840319A (en) * 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US5886049A (en) 1992-10-27 1999-03-23 Nippon Kayaku Kabushiki Kaisha Remedy for autoimmune diseases
ATE177008T1 (de) * 1992-10-27 1999-03-15 Nippon Kayaku Kk Verwendung von toremifene für die behandlung von sle
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5432168A (en) * 1993-12-27 1995-07-11 University Of Manitoba Method of treatment of hormone-unresponsive metastatic prostate cancer
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5571687A (en) * 1994-06-07 1996-11-05 Duke University Modulators of multidrug resistance transporters
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
EP2277514A1 (de) * 1998-05-07 2011-01-26 The University Of Tennessee Research Corporation Methode zur Vorbeugung von Prostatakrebs
US6413534B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
CA2352461A1 (en) * 1998-11-26 2000-06-02 Tomohito Fujii Pharmaceutical composition for periodic administration
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
US10201589B2 (en) 2013-12-11 2019-02-12 University Of Massachusetts Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA)
CA2971216A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE75947T1 (de) * 1984-08-02 1992-05-15 Labrie Fernand Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.

Also Published As

Publication number Publication date
IE67639B1 (en) 1996-04-17
US4990538A (en) 1991-02-05
KR910004185A (ko) 1991-03-28
CA2023630A1 (en) 1991-02-24
PH27064A (en) 1993-02-01
EP0415623A3 (en) 1991-04-03
AU633954B2 (en) 1993-02-11
AU6113390A (en) 1991-02-28
NZ234999A (en) 1997-06-24
KR0171893B1 (ko) 1999-02-01
HUT58511A (en) 1992-03-30
HU905276D0 (en) 1991-02-28
IE903044A1 (en) 1991-02-27
CA2023630C (en) 2002-02-19
JP3186759B2 (ja) 2001-07-11
EP0415623A2 (de) 1991-03-06
HU215913B (hu) 1999-03-29
JPH03163015A (ja) 1991-07-15

Similar Documents

Publication Publication Date Title
ZA906670B (en) Compounds for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
IL91361A0 (en) Tricyclic compounds,processes for the preparation thereof and pharmaceutical compositions containing the same
AP9100283A0 (en) Pharmaceutical compounds
ZA895838B (en) Pharmaceutical compounds
ZA89260B (en) Pharmaceutical compounds
GB9008123D0 (en) Pharmaceutical compounds
GB8916682D0 (en) Pharmaceutical compounds
IL99551A0 (en) Tricyclic compounds,processes for the preparation thereof and pharmaceutical compositions containing the same
GB9012252D0 (en) Pharmaceutical compounds
EP0443027A4 (en) Drug composition
GB8807016D0 (en) Organic compounds & their pharmaceutical use
ZA915450B (en) Pharmaceutical composition
GB9004023D0 (en) Pharmaceutical compounds
GB9016790D0 (en) Pharmaceutical compounds
GB9005653D0 (en) Anti-cancer compounds
GB9005968D0 (en) Anti-cancer compounds
GB9005967D0 (en) Anti-cancer compounds
GB9005652D0 (en) Anti-cancer compounds
GB8904040D0 (en) Pharmaceutical compounds
GB8911196D0 (en) Pharmaceutical compounds
GB8920738D0 (en) Pharmaceutical compounds
GB8906262D0 (en) Pharmaceutical compounds
GB9015410D0 (en) Solid drug form
GB8830078D0 (en) Pharmaceutical compounds
GB8826204D0 (en) Pharmaceutical compounds